Glenmark Of India Settles Lunesta Generics Dispute With Sepracor
This article was originally published in PharmAsia News
Executive Summary
India's Glenmark said it has settled a patent dispute with U.S.-based Sepracor that allows the generics maker to market its version of an insomnia drug by the end of 2013